December 21, 2014 1:06 PM ET

Pharmaceuticals

Company Overview of Polaris Pharmaceuticals, Inc.

Company Overview

Polaris Pharmaceuticals, Inc. engages in research and development of protein drugs to treat cancer. The company was founded in 2006 and is based in San Diego, California.

9373 Towne Centre Drive

Suite 150

San Diego, CA 92121

United States

Founded in 2006

Phone:

858-452-6688

Fax:

858-452-3199

Key Executives for Polaris Pharmaceuticals, Inc.

Chief Executive Officer and President
Co-Founder and Vice President of Medical Affairs
Chief Financial Officer
Age: 48
Executive Vice-President of Regulatory Affairs
Executive Director
Compensation as of Fiscal Year 2014.

Polaris Pharmaceuticals, Inc. Key Developments

Polaris Group Receives Orphan Drug Designation in United States and European Union for the Treatment of Malignant Pleural Mesothelioma

Polaris Group announced that its lead product candidate ADI-PEG 20 has received orphan drug designation for the treatment of malignant pleural mesothelioma in the United States and in the European Union. Orphan drug designation grants special status to a drug or biological product to treat a rare disease or condition. Having completed a successful randomized phase 2 trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma. Polaris Group is also conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma

Polaris Group announced that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current first line therapy, for the treatment of advanced hepatocellular carcinoma (HCC). Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, in combination with doxorubicin in HER2 negative breast cancer, in combination with nab-paclitaxel and gemcitabine for advanced pancreatic cancer, and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Doxorubicin in HER2 Negative Breast Cancer

Polaris Group announced that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with doxorubicin for the treatment of HER2 negative metastatic breast cancer. Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.

Similar Private Companies By Industry

Company Name Region
TriPath Oncology Inc. United States
Cardiokine, Inc. United States
Shire Development Inc. United States
Vanguard Pharmaceutical Corporation United States
AccuMed, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Polaris Pharmaceuticals, Inc., please visit www.polarispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.